See every side of every news story
Get Started
SubscribeLogin
Everton
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Viktor Orbán
Hamas
Basketball
Israel-Hamas Conflict
Manchester United
Elon Musk
Premier League
Soccer
Published • loading... • Updated

Zealand Pharma steadfastly upholds amylin-based obesity drug strategy - Pharmaceutical Technology

Summary by Pharmaceutical-technology.com
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and development timeline.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
pharmaceutical-technology.compharmaceutical-technology.com

Zealand Pharma steadfastly upholds amylin-based obesity drug strategy - Pharmaceutical Technology

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and development timeline.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news in on Thursday, February 20, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Denmark

Denmark

News
For You
Search
BlindspotLocal